Perspective Therapeutics
Price & Volume
Stats
See moreOpen | $2.97 |
Previous Close | $3.01 |
Day Range | $2.82-$3.11 |
52W Range | $1.96-$6.16 |
Market Cap | $343.2M |
Shares Short | 22M |
Financials
See moreRevenue (12 Mos) | $618,000 |
Revenue Growth (YoY) | -77.8% |
Gross Profit (12 Mos) | -$90.6M |
Diluted EPS | -$1.41 |
News
See moreYahoo Finance • 6 days ago
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
Yahoo Finance • 8 days ago
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials
Yahoo Finance • last month
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Yahoo Finance • 2 months ago
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
About
CEO | Mr. Johan M. Spoor |
CFO | Mr. Joel David Sendek |
Address | 2401 Elliott Avenue, Seattle, WA, United States, 98121 |
Sector | Healthcare |
Industry | Medical Devices |
Full-Time Employees | 163 |